ANXA2 has been found to be upregulated in many malignant tumors, including colorectal cancer, breast cancer, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma and neuroblastoma [27–29] . This evidence concerns the gene ANXA2 and hereditary clear cell renal cell carcinoma.